allovectin-7
Phase 3Small molecule
allovectin-7 is one of 36 small molecule programs targeting Melanoma. It is currently in Phase 3.
1
Indications
3
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Roferon-a
RochePhase 3
CC 5013
Bristol-Myers SquibbPhase 3
Methylphenidate Hydrochloride
TakedaPhase 3
Adjuvant Therapy
FFudan University
Phase 3
Bempegaldesleukin
NNektar Therapeutics
Phase 3
Interferon-Alpha-2a
RochePhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
allovectin-7
VVical
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Melanoma3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for allovectin-7. EMBL-EBI & Wellcome Sanger Institute.
- [4]